文献速递脑血管病

替奈普酶用于4.5至24小时急性缺血性卒中:随机对照试验荟萃分析

Tenecteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Stroke · 2025-10-13

该荟萃分析纳入4项多中心随机对照试验共1278例患者,比较静脉替奈普酶0.25 mg/kg与标准治疗或安慰剂在发病4.5至24小时内的疗效。替奈普酶显著提高90天极佳功能结局和再通率,且未增加症状性颅内出血或死亡风险;在未允许血管内取栓的亚组中获益更明显。

要点

  • 替奈普酶0.25 mg/kg可改善4.5-24小时急性缺血性卒中90天极佳功能结局。
  • 未增加症状性颅内出血或90天死亡风险。
  • 无取栓条件时替奈普酶额外获益更大,可作再灌注替代策略。

核心结论

  • 替奈普酶改善4.5至24小时急性缺血性卒中患者90天极佳功能结局和再通,不增加症状性颅内出血或死亡风险。
  • 在无法进行血管内取栓的情况下,延长时间窗内替奈普酶提供更大额外获益,可作为资源有限环境下的替代再灌注策略。

研究设计与样本

  • 检索比较静脉替奈普酶0.25 mg/kg与标准治疗或安慰剂在发病4.5至24小时内成人急性缺血性卒中的随机对照试验。
  • 纳入4项多中心随机对照试验,共1278例患者。
  • 采用随机效应荟萃分析,总体及按研究是否允许血管内取栓预设亚组(非取栓 vs 允许取栓)分层。

主要发现

  • 总体分析:替奈普酶显著提高90天极佳功能结局(mRS 0-1;OR 1.34,95%CI 1.06-1.71;P=0.02)和再通(OR 3.30,95%CI 1.59-6.84;P=0.001)。
  • 总体分析:良好功能结局(mRS 0-2)、再灌注和早期神经功能改善无显著差异。
  • 非取栓亚组(596例):替奈普酶显著改善极佳功能结局(OR 1.46,95%CI 1.02-2.08;P=0.04)、良好功能结局(OR 1.50,95%CI 1.07-2.09;P=0.02)、再通(OR 6.17,95%CI 3.36-11.33;P<0.00001)和早期神经功能改善(OR 3.21,95%CI 1.82-5.66;P<0.0001)。
  • 允许取栓亚组(682例):替奈普酶仅改善再通(OR 2.36,95%CI 1.34-4.17;P=0.003)。
  • 总体及亚组分析中,替奈普酶与对照组在症状性颅内出血或90天死亡风险上无显著差异。

关键数值与推荐

  • 纳入标准:成人急性缺血性卒中发病4.5至24小时内,比较静脉替奈普酶0.25 mg/kg与标准治疗或安慰剂。
  • 主要结局:90天极佳功能结局(改良Rankin量表评分0-1)。
  • 亚组分层:按研究是否允许血管内取栓分为非取栓组和允许取栓组。

临床怎么用

  • 对于发病4.5至24小时且无血管内取栓条件的急性缺血性卒中患者,可考虑静脉替奈普酶0.25 mg/kg以改善功能结局和再通。
  • 在允许血管内取栓的环境中,替奈普酶的主要额外获益限于再通改善,需结合整体再灌注策略评估。
  • 替奈普酶未增加症状性颅内出血或死亡风险,但临床使用仍需遵循当地指南和个体化评估。

局限性

  • 仅纳入4项随机对照试验,总样本量1278例,亚组样本量较小。
  • 非取栓与允许取栓亚组为研究水平分层,可能存在混杂。
  • 未报告部分结局的详细数值,长期获益需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether TNK (tenecteplase) benefits patients with acute ischemic stroke treated within 4.5 to 24 hours remains uncertain, and no previous meta-analysis has differentiated between clinical settings where endovascular thrombectomy (EVT) is unavailable or permitted, leading to pooled distinct clinical contexts and obscuring a clear estimation of TNK's net effect. METHODS: We searched for randomized controlled trials comparing intravenous TNK of 0.25 mg/kg with standard care or placebo in adults within 4.5 to 24 hours after acute ischemic stroke onset. The primary outcome was excellent functional outcome (modified Rankin Scale score, 0-1) at 90 days, with additional efficacy and safety end points. A random-effects meta-analysis was performed both overall and within predefined subgroups, stratified by whether EVT was permitted in individual studies (non-EVT versus EVT-permitted). RESULTS: Four multicenter randomized controlled trials enrolling 1278 patients were included. TNK significantly increased excellent functional outcome (odds ratio [OR], 1.34 [95% CI, 1.06-1.71]; P=0.02) at 90 days and recanalization (OR, 3.30 [95% CI, 1.59-6.84]; P=0.001) compared with the control group, whereas good functional outcome (modified Rankin Scale score, 0-2), reperfusion, and early neurological improvement did not differ significantly. Subgroup analyses of 596 patients in the non-EVT subgroup showed that TNK significantly improved excellent functional outcome (OR, 1.46 [95% CI, 1.02-2.08]; P=0.04), good functional outcome (OR, 1.50 [95% CI, 1.07-2.09]; P=0.02), recanalization (OR, 6.17 [95% CI, 3.36-11.33]; P<0.00001), and early neurological improvement (OR, 3.21 [95% CI, 1.82-5.66]; P<0.0001). However, in the EVT-permitted subgroup of 682 patients, TNK only improved recanalization (OR, 2.36 [95% CI, 1.34-4.17]; P=0.003). No significant differences were observed between TNK and control in the risks of symptomatic intracerebral hemorrhage or 90-day mortality, either in the overall or subgroup analyses. CONCLUSIONS: TNK improves excellent functional outcomes and recanalization in patients with acute ischemic stroke treated within 4.5 to 24 hours, without increasing the risks of symptomatic intracerebral hemorrhage or mortality. Notably, extended-window TNK provides greater additional benefits when EVT is inaccessible, establishing its role as an alternative reperfusion strategy in resource-limited settings.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Wang Z, Li J, Wang X, et al. Tenecteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: A Meta-Analysis of Randomized Controlled Trials. Stroke. 2025. PMID: 41078125. doi:10.1161/STROKEAHA.125.053256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。